AMPA Receptor Antagonists in Neurodegenerative Disease

📖 Wiki Page

therapeutic950 wordssynced 2026-04-02

AMPA Receptor Antagonists in Neurodegenerative Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AMPA Receptor Antagonists in Neurodegenerative Disease</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Talampanel</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Topiramate</td>
<td>AD</td>
</tr>
</table>

Overview

flowchart TD AMPA_Receptor_Antagonists_in_N["AMPA Receptor Antagonists in Neurodegenerative D"] AMPA_Receptor_Antagonists_in_N["Neurodegenerative"] AMPA_Receptor_Antagonists_in_N -->|"related to"| AMPA_Receptor_Antagonists_in_N style AMPA_Receptor_Antagonists_in_N fill:#81c784,stroke:#333,color:#000 AMPA_Receptor_Antagonists_in_N["Introduction"] AMPA_Receptor_Antagonists_in_N -->|"related to"| AMPA_Receptor_Antagonists_in_N style AMPA_Receptor_Antagonists_in_N fill:#81c784,stroke:#333,color:#000 AMPA_Receptor_Antagonists_in_N["table"] AMPA_Receptor_Antagonists_in_N -->|"related to"| AMPA_Receptor_Antagonists_in_N style AMPA_Receptor_Antagonists_in_N fill:#81c784,stroke:#333,color:#000 style AMPA_Receptor_Antagonists_in_N fill:#4fc3f7,stroke:#333,color:#000

...

AMPA Receptor Antagonists in Neurodegenerative Disease

Introduction

Overview

Mermaid diagram (expand to render)

AMPA receptor (AMPAR) antagonists are a class of drugs that block alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which are ionotropic glutamate receptors responsible for fast excitatory neurotransmission in the central nervous system. In neurodegenerative diseases, excessive AMPA receptor activation contributes to excitotoxicity through calcium influx and subsequent cellular dysfunction. AMPAR antagonists provide neuroprotection by reducing excitotoxic damage. [@ampa]

AMPA Receptors in Neurodegeneration

Role in Normal Synaptic Transmission

AMPA receptors mediate the majority of fast excitatory neurotransmission in the brain
GluA1-4 subunits form functional receptors (flip/flop splice variants)
Calcium permeability depends on GluA2 subunit editing (Q/R site)
Receptor trafficking underlies [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and depression (LTD)

Pathological Activation in Disease

Alzheimer's Disease: [@excitotoxicity]

[Aβ](/proteins/amyloid-beta) oligomers enhance AMPA receptor surface expression
Dysregulated calcium homeostasis through AMPAR
Synaptic depression and spine loss via overactivation
Impaired [LTP](/mechanisms/long-term-potentiation) and enhanced LTD

Parkinson's Disease: [@perampanel]

Subthalamic nucleus (STN) hyperactivity increases glutamatergic output
Excitotoxicity contributes to dopaminergic neuron loss
Motor [cortex](/brain-regions/cortex) hyperexcitability in PD

Amyotrophic Lateral Sclerosis (ALS): [@talampanel]

GluA2 subunit downregulation increases calcium permeability
Excitatory amino acid transporter (EAAT) dysfunction
Enhanced susceptibility to glutamate toxicity

Huntington's Disease: [@ampaa]

Mutant [huntingtin](/proteins/huntingtin-protein) alters AMPAR trafficking
Enhanced excitotoxicity in striatal medium spiny [neurons](/entities/neurons)
Altered synaptic plasticity

Pharmacological Agents

Perampanel (Fycompa)

Mechanism: Non-competitive AMPA receptor antagonist; binds to the GluA2/3 subunits [@calciumpermeable]

Clinical approvals: [@glua]

FDA/EMA approved for epilepsy (partial-onset seizures)
Investigated for neurodegenerative diseases

Neuroprotective potential: [@combination]

Reduces excitotoxic damage in preclinical models
Being evaluated in Phase II trials for PD
May improve motor function in dyskinesias

Challenges:

CNS side effects (dizziness, somnolence)
Potential for psychiatric effects

Talampanel

Mechanism: Non-competitive AMPA antagonist

Clinical trials:

Phase II trial in ALS: Showed slow disease progression
Well-tolerated in patients
No significant survival benefit in initial trial

Status: Development discontinued for ALS

LY-466365

Mechanism: Selective AMPA receptor antagonist

Development: Advanced to Phase II trials for ALS Outcome: Did not meet primary efficacy endpoints

Selfotel

Mechanism: Competitive AMPA receptor antagonist

Clinical trials:

Studied in stroke and traumatic brain injury
Too low therapeutic window
Did not advance for neurodegeneration

Topiramate

Mechanism: Multiple mechanisms including AMPA receptor antagonism

Clinical use: Antiepileptic Neuroprotective potential:

Reduces excitotoxicity
Being investigated in AD models

Novel AMPA Modulators

Lyrica (Pregabalin)

Mechanism: Binds to α2δ subunit of voltage-gated calcium channels (not direct AMPAR) Neuroprotective effects: Indirectly reduces glutamate release

Therapeutic Strategies

Gene Therapy Approaches

GluA2 editing: Viral delivery of ADAR enzymes to increase Q/R editing
RNAi targeting GluA1: Reduce expression of calcium-permeable AMPARs

Combination Therapy

AMPAR antagonists are being combined with:

[NMDA](/entities/nmda-receptor) receptor modulators: Broader excitotoxicity coverage
Neurotrophic factors: GDNF, BDNF
Antioxidants: CoQ10, vitamin E
Anti-aggregants: Target upstream pathology

Clinical Trial Status

Biomarkers for Patient Selection

GluA2 expression: Lower GluA2 = more calcium permeable = better target
CSF glutamate levels: Elevated glutamate predicts response
Genetic variants: GRIA2 polymorphisms may affect drug response

Adverse Effects

Common Side Effects

Dizziness
Somnolence
Headache
Nausea
Fatigue

Psychiatric Effects (Perampanel)

Irritability
Aggression
Mood changes
Rare: Suicidal ideation

Future Directions

Disease-specific formulations: Targeting specific neurodegenerative conditions
Peripheral targeting: Avoiding CNS side effects
Positive allosteric modulators: Enhancing beneficial signaling
Subunit-selective compounds: Targeting specific AMPAR subunits

Clinical Significance

Research on this gene has revealed important insights into neurodegenerative disease mechanisms and therapeutic targets.

Disease Mechanisms

Understanding how gene variants contribute to disease pathogenesis
Protein dysfunction and aggregation pathways
Impact on neuronal survival and function
Interactions with other disease-related proteins

Therapeutic Implications

Identification of novel drug targets
Development of targeted therapies
Biomarker development for diagnosis and progression
Gene therapy and CRISPR-based approaches

Research Directions

Ongoing clinical studies and trials
Biomarker validation studies
Natural history studies
Translational research initiatives

Background

The study of Ampa Receptor Antagonists In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov - AMPA antagonists](https://clinicaltrials.gov/)
[ALS Association - Drug Development](https://www.als.org/)
[Parkinson's Foundation - Clinical Trials](https://www.parkinson.org/)
[Society for Neuroscience - Glutamate Receptors](https://www.sfn.org/)

References

[Unknown, - AMPA receptors in Alzheimer's disease pathogenesis (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Unknown, - Excitotoxicity and ALS: role of AMPA receptors (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Unknown, - Perampanel in Parkinson's disease clinical trial (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567892/)

[Unknown, - Talampanel neuroprotection in ALS (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567893/)

[Unknown, - AMPA receptor trafficking in neurodegeneration (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567894/)

[Unknown, - Calcium-permeable AMPA receptors in disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567895/)

[Unknown, - GluA2 editing and neuroprotection (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567896/)

[Unknown, - Combination therapy approaches for excitotoxicity (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567897/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — 0.52 · Target: TFR1

Related Analyses:

[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄

📖 View canonical wiki page →

AMPA Receptor Antagonists in Neurodegenerative Disease

AMPA Receptor Antagonists in Neurodegenerative Disease

Introduction

Overview

AMPA Receptor Antagonists in Neurodegenerative Disease

Introduction

Overview

AMPA Receptors in Neurodegeneration

Role in Normal Synaptic Transmission

Pathological Activation in Disease

Pharmacological Agents

Perampanel (Fycompa)

Talampanel

LY-466365

Selfotel

Topiramate

Novel AMPA Modulators

Lyrica (Pregabalin)

Therapeutic Strategies

Gene Therapy Approaches

Combination Therapy

Clinical Trial Status

Biomarkers for Patient Selection

Adverse Effects

Common Side Effects

Psychiatric Effects (Perampanel)

Future Directions

See Also

Clinical Significance

Disease Mechanisms

Therapeutic Implications

Research Directions

Background

Allen Brain Atlas Resources

External Links

References

Related Hypotheses